

Understanding the stabilization mechanism of polyvinyl alcohols (Parteck® MXP) in ASDs by structure-related properties and PC-SAFT modeling

David Luedeker*, Thomas Kipping*, Christian Luebbert**

MILLIPORE SIGMA


Purpose

- For the development of amorphous solid dispersions (ASDs), the physical stability of the formulation is a key challenge determining their performance additional to dissolution and solubility.
- Selecting the right polymer/API combination early on is crucial for proper CMC development.
- In this work, a thermodynamic modelling approach (PCSAFT)^{1,2} is utilized to predict API/polymer compatibility leveraging the potential to reduce experimental screening efforts.

Objectives

- Generate a PC-SAFT model for semi-crystalline polymer polyvinyl alcohol (PVA – Parteck® MXP).
- Calculate ASD phase diagrams of PVA and various model APIs (indomethacin (IND), naproxen (NAP) and itraconazole (ITR)) and validate predictions.
- Calculate PC-SAFT activity coefficients to enable API/PVA compatibility predictions, thus providing an intermolecular interaction-based assessment of beneficial API/PVA combinations.

Methods



- API crystallization and miscibility
- Predictive interaction screening for many APIs
- Model for semi-crystalline polymer Parteck® MXP 4-88
- Validation of predicted phase diagrams via differential scanning calorimetry (DSC)
- Hot-melt extrusion and storage
- Crystallinity detection via X-ray and DSC




Figure 2. Modeled API/PVA4-88 phase diagrams of (A) IND/PVA4-88, (B) NAP/PVA4-88 and (C) ITR/PVA4-88 containing the PC-SAFT modeled crystalline solubility in amorphous PVA4-88 (magenta line) and the Kwei modeled glass-transition temperature (yellow line) as well as the predicted miscibility gap between PVA4-88 and ITR (purple). Symbols are experimental data points obtained from DSC measurements.

MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, the Vibrant M, SAFC and Parteck are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. Lit. No. MS_PS11634EN 11/2022

Results

- Extension of PC-SAFT approach to hot-melt extruded solid dispersions containing semi-crystalline polymer PVA (Parteck® MXP) as carrier matrix.
- Model assumptions for semi-crystalline polymer:
 - API solely dissolves in the amorphous parts of the polymer (66 w%): amorphous vinyl acetate (Vac)/vinyl alcohol (VA) ratio is 68/32 w%
 - Crystalline VA polymer fractions are considered unavailable for API interactions (34 w%)




Figure 1. Scheme of the semi-crystalline PVA polymer exhibiting crystalline domains being unavailable for API interactions and amorphous domains interacting with enclosed APIs.

API	GFA class	T _m /°C	T _g /°C	Max. stable DL in Parteck® MXP	Ref.
IND	3	161	45	30 wt%	5
NAP	1	153	-3	10 wt%	6
ITR	3	168	58	10 wt%	5

Table 1. Physical properties of the investigated APIs and the maximal observed stable drug load (DL) during stability studies (remained amorphous for investigated period of time).




Figure 3. Via PC-SAFT predicted API/PVA4-88 activities in 20 wt% ASDs at 25 °C. Low values represent strong interactions and high ASD stabilization potential, high values represent weak interactions and low ASD stabilization potential.

- Phase diagrams of IND/PVA and NAP/PVA appear very similar showing a maximum for T_g indicating strong API/polymer interactions.
- NAP/PVA: T_g is significantly decreased at higher drug loadings reflecting the lower GFA (glass-forming ability) and low kinetic stabilization potential of pure amorphous NAP.
- ITR/PVA: immiscibility predicted above 12 w%, the new evolving amorphous phase contains 99.9 w% ITR.
- Calculations were confirmed by experimental data: GFA, highest drug load (DL) in PVA and physical stability.
- These calculations are full predictions and require no additional experimental data, they thus serve as screening tool for early formulation development.
- Compounds exhibiting aromatic nitrogen acceptor functional groups show stronger interactions with PVA, likely due to the formation of the strong OH...N hetero synthon.⁴

Conclusions

- Successful extension of PC-SAFT approach to the semicrystalline polymer PVA (Parteck® MXP).
- Parteck® MXP shows stabilizing properties most likely due to interactions of the hydroxyl groups with hydrogen bonding acceptor moieties of the APIs.
- PC-SAFT was utilized as a screening tool for API/polymer compatibility.
- With Parteck® MXP good stabilizable API candidates are predictable.
- In future: validation interaction screenings with ssNMR to experimentally confirm the stabilization mechanism.
- In future: assess the impact of varying hydrolysis degree on stabilization potential.

References

- Prudic A, Ji Y, Sadowski G. Thermodynamic phase behavior of API/polymer solid dispersions. *Mol Pharm.* 2014; 11(7):2294-304.
- Lehmkemper K, Kyeremateng SO, Heinzerling O, Degenhardt M, Sadowski G. Long-Term Physical Stability of PVP- and PVPVA-Amorphous Solid Dispersions. *Mol Pharm.* 2017; 14(1):157-171.
- Prudic A, Ji Y, Luebbert C, Sadowski G. Influence of humidity on the phase behavior of API/polymer formulations. *Eur J Pharm Biopharm.* 2015; 94:352-62.
- Luedeker D, Gossmann R, Langer K, Brunklaus G. Crystal Engineering of Pharmaceutical Cocrystals: "NMR Crystallography" of Niclosamide Co-crystals. *Cryst. Growth & Des.* 2016; 16(6), 3087-3100.
- Baird JA, Van Eerdenbrugh B, Taylor LS. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. *J Pharm Sci.* 2010; 99(9):3787-806.
- Mahlén D, Bergström CAS. Early drug development predictions of glass-forming ability and physical stability of drugs. *Eur. J. Pharm. Sci.* 2013; 49(2) 323-332.

* MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany.
** amofor GmbH, Otto-Hahn-Straße 15, 44227 Dortmund, Germany.

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

amofor
enabling formulations

SAFC®

Pharma & Biopharma Raw
Material Solutions